Optimizing vascular access outcomes remains an ongoing challenge for clinical
nephrologists. All other things being equal, fistulas are preferred over grafts, and grafts are …

Patent vascular access is a prerequisite for adequate haemodialysis, and is a major
determinant of quality of life and long-term survival of patients with end-stage renal disease …

PURPOSE: To determine the primary and secondary patency rates for fistulas treated with
angioplasty, as well as clinical predictors of fistula patency after angioplasty. MATERIALS …

Background. Stenosis is the main cause of arteriovenous fistula (AVF) failure. It is unclear,
however, if surveillance for stenosis enhances AVF function and longevity and if there is an …

PURPOSE: To retrospectively evaluate success and midterm patency after percutaneous
thrombectomy, lytic therapy, and angioplasty for thrombosed autogenous arteriovenous …

PURPOSE: The present study sought to evaluate the performance of the Arrow-Trerotola
Percutaneous Thrombolytic Device (PTD) in the treatment of native fistula thrombosis in a …

The number of people worldwide living with end-stage renal disease is increasing.
Arteriovenous fistulas are the preferred method of vascular access in patients who will …

Objective: To evaluate the initial clinical success and long-term patency rates of
percutaneous transluminal angioplasty (PTA) using a venous approach for dysfunctional …

Background. Surgery is an established treatment for stenosed and thrombosed forearm
arteriovenous fistulae (AVFs), but the literature on its outcome is limited. We report our …

In February 2008 a multidisciplinary study group was established in Germany to improve the
treatment of patients with potential vascular access problems. As one of the first results of …